Author

S. K. Sandhu

Observed names: S.K. Sandhu, Sandhu SK

Institutions: The University of Melbourne, Peter MacCallum Cancer Centre

Observed institutions: The University of Melbourne, Peter MacCallum Cancer Centre

OpenAlex ID: A5075464784

First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.

2010 · S. K. Sandhu, R. M. Wenham, et al. · Journal of Clinical Oncology · 34

Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel.

2011 · H. I. Scher, G. Heller, et al. · Journal of Clinical Oncology · 22

A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941.

2010 · R. D. Baird, R. S. Kristeleit, et al. · Journal of Clinical Oncology · 9

Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)

2026 · A.Y. Zhang, H. Thomas, et al. · Annals of Oncology

Value of early circulating tumor cells dynamics to estimate docetaxel benefit in metastatic castration-resistant prostate cancer (mCRPC) patients

2021 · Lozano R, Lorente D, et al. · Newcastle University ePrints (Newcastle Univesity)

Works count: 5

Citation count: 65

H-index: 3

I10-index: 2